Renal medullary carcinoma (RMC) is a rare kidney cancer with poor outcomes. We analyzed treatment outcomes in patients with RMC and performed targeted sequencing of tumors to identify unique molecular features. Although responses to platinum-based therapy were found, these were short-lived. There was uniform loss of SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1 (SMARCB1) through translocations and deletions, and further research should go into targeting this pathway. Background: Renal medullary carcinoma (RMC) is a rare and aggressive type of kidney cancer that primarily affects young adults with sickle cell trait; outcomes are poor despite treatment. Identifying molecular features of this tumor could provide biologic rationale for novel targeted therapies. The objective was to report on clinical outcomes with systemic therapy and characterize molecular features. Patients and Methods: This was a retrospective analysis on 36 patients given a pathologic diagnosis of RMC at one institution from 1995 to 2015. Tumors were analyzed for expression of SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1 (SMARCB1) through immunohistochemistry and for genomic alterations with fluorescence in situ hybridization for SMARCB1, and targeted next-generation sequencing. Time from initiation of therapy to progression of disease and overall survival were calculated using the KaplaneMeier method. Results: The median age in the cohort was 28 (range, 12-72) years, and all patients tested had sickle cell trait. Overall survival was 5.8 months (95% confidence interval [CI], 4.1-10.9) and for 12 patients who received platinum-based therapy, median progression-free survival was 2.5 months (95% CI, 1.2-not reached). A total of 10 available tumors underwent analysis with fluorescence in situ hybridization for SMARCB1; this revealed loss of heterozygosity with concurrent translocation in 8, and biallelic loss in 2. Next-generation targeted sequencing showed no recurring mutations. Conclusions: Outcome was generally poor in this cohort of patients with RMC. Uniform loss of SMARCB1 is a key molecular feature in this tumor and mechanism of loss appears to be mostly through translocations and deletions.
Introduction
Renal medullary carcinoma (RMC) is a rare and aggressive type of kidney cancer that primarily affects young adults with sickle cell trait. It was first described in 1995, when Davis et al reported on a series of cases of aggressive kidney cancer whose histology predicted presence of red blood cell sickling. Since then, other series have confirmed that most affected patients have either sickle cell trait, or rarely, sickle cell disease, with a median age of diagnosis ranging between 15 and 26 years. [1] [2] [3] Most patients present with advanced disease and, despite therapy, overall survival (OS) is usually < 1 year. There is no defined standard treatment for this rare entity. Most patients receive platinum-based therapy on the basis of extrapolation from therapies used in other distal nephron tumors, however, there have been no prospective studies or large retrospective series to validate this approach. Small retrospective series have reported that only a small number of patients respond to chemotherapy. 4 Targeted therapy with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin (mTOR) inhibitors have also been used with disappointing results. 5 Because of the aggressive nature and poor outcomes of this disease, there is great need to identify novel molecular therapeutic targets. Several studies have reported loss of expression of SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1 (SMARCB1) as a recurrent feature of RMC. SMARCB1 is a core subunit of the switch/sucrose nonfermenting (SWI/SNF) complex, which is involved in adenosine triphosphate-dependent chromatin remodeling, and has been implicated in the development of rare pediatric tumors, among other malignancies. 6 Because of the lack of effective therapies and poor prognosis of RMC patients, further investigation into the mechanism of loss of SMARCB1, as well as identification of other genetic alterations, might be important for novel therapeutic strategies.
In this study, we retrospectively identified all cases of RMC diagnosed at our center from 1995 to 2015. The objective was to report on clinical outcomes to systemic therapy and characterize the genomic features of these tumors.
Patients and Methods

Study Population
Before a retrospective review of patients with RMC, the Memorial Sloan Kettering Cancer Center (MSKCC) institutional review board approved this study. Patients were identified from an institutional database that includes all pathology reports from 1993 to present, with data cutoff of September 25, 2015. Patients were included if the pathology report documented RMC. Electronic medical records were then queried for clinical data.
Response to Therapy
Imaging studies were performed per standard of care at MSKCC, and consisted of computed tomography (CT) imaging of the chest, abdomen and pelvis, or chest x-ray and abdominal magnetic resonance imaging if CT was not available. All imaging for this study was reviewed by a radiologist (J.C.) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. 7 Patients who had pre-as well as post-therapy imaging, and received at least 1 cycle or month of therapy, were evaluable for response according to RECIST. Patients were considered to have progression of disease if there was either progression according to RECIST criteria or if they discontinued therapy because of worsening symptoms or decline in performance status.
Data Analysis
Baseline characteristics and treatment received were summarized descriptively. OS was calculated using KaplaneMeier estimates from the date of initial oncology visit until death, and patients who were still alive at the data cutoff were censored at date of last follow-up. Progression-free survival (PFS) was calculated using KaplaneMeier estimates from initiation of systemic therapy until date of radiographic or clinical progression, or death, whichever was first.
Immunohistochemical Analysis
Patients who had signed consent for specimen research use and who had available formalin-fixed, paraffin-embedded (FFPE) tissue were further evaluated. All samples were again reviewed by a genitourinary pathologist (Y.-B.C.) to confirm diagnosis, and to select for areas of maximum tumor content for DNA extraction. Immunohistochemistry for SMARCB1 was performed in 5-mm FFPE tissue sections using an automated Ventana Benchmark system (Ventana Medical Systems) and a mouse monoclonal antibody (1:100, BAF47; BD Bioscience).
Fluorescence In Situ Hybridization Analysis
Fluorescence in situ hybridization (FISH) analysis was performed on paraffin sections using a 3-color probe mix comprising bacterial artificial chromosome clones for 5 0 SMARCB1 (RP11-248J22, 
Genomic Analysis
If patients had blood samples available, these were used for DNA extraction for matched normal control. Genomic alterations in key cancer-associated genes were identified using exome capture using hybridization followed by next-generation sequencing (NGS) using the Integrated Mutation Profiling of Actionable Cancer Targets assay, which included 341 cancer-related genes in an earlier iteration (n ¼ 2), and 410 genes in the updated platform (n ¼ 4). 8 For tumors with no matched normal controls for sequencing, common single-nucleotide polymorphisms were filtered out. Because remaining rare variants could not be reliably categorized as somatic or germ line, they were all assessed for possible germ line pathogenicity according to American College of Medical Genetics (ACMG) standards.
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Results
Patient and Tumor Characteristics
Thirty-six patients were diagnosed with RMC from 1995 to 2015. Key patient and tumor characteristics are summarized in Table 1 . The median age at diagnosis was 27.5 (range, 12-72) years, and 27 patients (75%) were male. Twenty-seven patients had hemoglobin electrophoresis results, and all showed sickle cell trait. Of the 24 patients who self-reported race, 20 (83%) were African-American. Of the 4 patients who identified as e988 -Clinical Genitourinary Cancer December 2017
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Caucasian, 2 had sickle cell trait and 2 had unknown sickle cell status. Most patients were symptomatic at presentation, with only 1 patient whose tumor was found incidentally, and the median maximum tumor dimension was 5.9 cm (range, 2.5-14.2 cm). Most tumors were right-sided (67%). Of the 33 patients whose staging was known at diagnosis, 27 (75%) presented with metastatic disease at diagnosis. Of the 6 patients who initially presented with localized disease, all but 1 had disease recurrence at time of last follow-up. The most common sites of metastases were lymph nodes (86%), lung (81%), bone (44%) soft tissue (39%), and liver (36%). Two patients had documented brain metastases.
Survival Outcome and Treatment Response
With a median follow-up of 5.1 months, OS in the 32 evaluable patients was 5.8 months (95% confidence interval [CI], 4.1-10.9; Figure 1 ). Eighteen patients received first-line therapy at our institution, 11 second-line, and 3 third-line or more. Most patients received a platinum combination (n ¼ 12), either as first or secondline therapy. Of these patients, 11 had radiographic or clinical progression at time of analysis, with a median PFS of 2.5 months (95% CI, 1.2-not reached; Figure 2 ); 10 were evaluable according to RECIST 1.1 criteria: 4 patients had a partial response, 2 had stable disease, 4 had progressive disease (Table 2 ). Platinum combination therapies used included: carboplatin and gemcitabine (n ¼ 6), cisplatin and gemcitabine (n ¼ 3), cisplatin and paclitaxel (n ¼ 1), carboplatin and paclitaxel (n ¼ 1), and carboplatin/gemcitabine/paclitaxel (n ¼ 1).
Five patients received mTOR inhibitors or VEGF-targeted therapy. Therapies used included everolimus with bevacizumab as part of a clinical trial (n ¼ 2), sunitinib (n ¼ 2), and temsirolimus (n ¼ 1); no patients had objective responses. 10 Other therapies used included monotherapies with gemcitabine, pemetrexed, doxorubicin, capecitabine; none produced a durable response. One patient received MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) and another TIP (paclitaxel/ifosfamide/cisplatin) after disease progressing during treatment with carboplatin/gemcitabine; neither had a durable response. Of note, 1 patient received bortezomib and had a complete response; this case has been previously published. 11 The patient was lost to follow-up after 72 months and tumor molecular analysis was not performed.
Molecular Characteristics
Twenty-three patients had tumor tissue available for staining for SMARCB1 (Integrase interactor 1) expression, and all had loss of SMARCB1. Ten patients had sufficient tissue for FISH analysis for SMARCB1 (Table 3) . FISH analysis revealed loss of heterozygosity with concurrent translocation in 8 patients, and biallelic loss of SMARCB1 in 2 patients. Six patients had tissue available for NGS (Table 3) , with 3 run with matched normal and 3 run without matched normal. No mutations of SMARCB1 were identified through NGS. The only recurrently altered genes were DNA Polymerase Epsilon, Catalytic Subunit and MTOR in samples without a matched germ line control for filtering; on the basis of allele frequency and ACMG criteria, these variants were thought to be probably germ line "variants of unknown significance" (see Supplemental Table 1 in the online version). 
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Discussion
Renal medullary carcinoma is a rare subtype of renal cell carcinoma with an aggressive clinical course, historically grouped with other distal nephron tumors such as collecting duct carcinoma. There has been debate, however, on whether these neoplasms are within a spectrum or whether they are 2 separate entities. 12, 13 For example, RMC has distinct clinical features-compared with collecting duct carcinoma, patients with Response assessed according to RECIST version 1.1 criteria.
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RMC are younger, predominantly male, and have sickle cell trait or disease. 14 Our study cohort was typical of those previously reported-most patients were male (75%), presented with metastatic disease (75%), and all patients tested had sickle cell trait. Tumors were highly aggressive, with most patients developing metastases in the lymph nodes and lung, and with a poor median OS of 5.8 months.
Although there is no standard treatment for RMC, because of pathologic features similar to distal nephron tumors, it has historically been treated with platinum-based regimens also commonly used in collecting duct carcinomas. 15 Because of the rarity of RMC,
prospective treatment studies are difficult to conduct, and evidence for effectiveness of therapy is limited to case reports and small series. In this study, we analyzed responses to platinum-based therapies in 10 patients evaluable according to RECIST criteria. Responses to platinum-based therapy were seen in 40% of patients, with an additional 20% with stable disease. However, these responses were short-lived, with a median PFS of 2.5 months. Furthermore, no patients had a response to mTOR inhibitors or VEGF-targeted therapies. New therapies are clearly needed for this disease. We sought to investigate unique molecular markers that could become the target of novel therapies. Pathologically, a consistent finding in RMC has been the loss of staining for SMARCB1.
2 SMARCB1 is a component of the chromatin remodeling complex SWI/SNF and acts as a tumor suppressor, with germline heterozygous loss leading to a rhabdoid predisposition syndrome. 16 Previous studies characterizing the mechanism of loss of SMARCB1 have shown that RMC tumors often harbor somatic mutations or monoallelic loss of SMARCB1.
17
In the study cohort, all patients had loss of SMARCB1, either through hemizygous deletions and additional translocation in the remaining allele, or biallelic deletions. In comparison, in collecting duct carcinoma, which is morphologically similar to RMC, only infrequent truncating mutations in SMARCB1 have been seen (18% of tumors in a series). 18 NGS revealed no additional recurrent mutations in matched tumor and normal samples. This finding is in concordance with a previously published report of 5 cases of RMC, in which 4 tumors harbored translocations, and a fifth tumor showed biallelic loss. 19 Although we did not perform further analysis to identify the translocation partner, in that study, 4 different translocation partners were identified. Together, this suggests that these genetic alterations in SMARCB1 induce loss of function as opposed to a de novo function. Additional studies would be necessary to determine whether loss of SMARCB1 is necessary and sufficient for tumorigenesis and how sickle cell trait contributes to pathogenesis. 
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Biallelic loss of SMARCB1 is found in other aggressive neoplasms including malignant rhabdoid tumors, atypical teratoid/ rhabdoid tumors, and epithelioid sarcomas. 16 Unlike rhabdoid tumors, which mostly harbor SMARCB1 deletions or mutations, it appears that in RMC, SMARCB1 alterations are mostly hemizygous deletions with concurrent translocations or homozygous deletions. 20, 21 There has been recent interest in targeting enhancer of Zeste homologue (EZH2) in SMARCB1-deficient tumors. EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which catalyzes methylation of specific lysine residues of histone H3, and aberrant EZH2 methylation has been associated with malignancy. 22, 23 SWI/SNF and PRC2 have antagonistic functions and loss of SMARCB1 function leads to overactivation of PRC2. 24 This has led investigators to test EZH2 inhibitors in SMARCB1-deficient tumors. Preclinical data in SMARCB1-deficient cell lines has shown EZH2 inhibitors can lead to apoptosis and differentiation. 25, 26 There is an ongoing phase II trial of the EZH2 inhibitor tazemetostat in SMARCB1-deficient tumors. This study confirms that RMC appears uniformly deficient in SMARCB1 through biallelic inactivation, and should be considered a candidate for testing EZH2 inhibitor therapy. This study is limited by several factors. First, treatment responses were assessed in a retrospective fashion, although the radiologist was blinded to treatment received. The small number of tumors available for sequencing limits definite conclusions on other recurrently altered genes. Nevertheless, despite these limitations, this study shows that RMC is molecularly distinct from other renal tumors and characterized by SMARCB1 translocations and deletions, and that platinum-based chemotherapy has activity in this disease.
Conclusion
These findings show that RMC is an aggressive malignancy that can respond to platinum-based chemotherapy, however, responses are short-lived and OS remains poor. RMC is characterized by deletions and translocations of SMARCB1, which codes for a protein in the SWI/SNF chromatin remodeling complex. Mutations in the SWI/SNF complex are poorly understood, and more research is needed to understand the role of SMARCB1 in the pathogenicity of RMC and potential targeted therapies. Clinical trials are difficult to conduct in rare diseases, making translational work an important way to uncover potential therapies.
Clinical Practice Points
Renal medullary carcinoma is a rare and aggressive type of kidney cancer usually treated with platinum-based therapy on the basis of experience with urothelial carcinoma and limited case series. Forty percent of patients had a partial response to platinumbased therapy, but these responses were short-lived, and there were no responses to targeted anti-VEGF or mTOR therapies. Fluorescence in situ hybridization for SMARCB1 showed loss of heterozygosity with concurrent translocation in most tumors, and biallelic loss in the remaining. Because of the poor outcomes with conventional therapy, research should go into targeting the SMARCB1 pathway. 
